New imaging registry aims to sharpen cancer treatment precision
NCT ID NCT07636148
First seen Jun 25, 2026 · Last updated Sep 02, 2026 · Updated 4 times
Summary
This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner called spectral angio-CT captures extra imaging details. The goal is to see how this extra information relates to treatment success and could improve future planning and guidance. No experimental treatments are given, and patients receive standard care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better plan and predict outcomes for minimally invasive cancer treatments using advanced imaging.
- What could go wrong
- This is an observational registry, not a treatment trial. It collects data only and does not test a new therapy, so direct patient benefits are not expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients (18 years or older) with solid tumors undergoing clinically indicated minimally invasive cancer treatments at participating centers in the Netherlands and France. Eligible procedures include percutaneous techniques such as thermal ablation, and catheter-based approaches such as transarterial embolization, chemoembolization, and radioembolization, for tumors in organs including the liver, kidney, lung, and musculoskeletal system. The spectral angio-CT must be used as part of standard clinical care during the procedure. Patients who are incapacitated or have psychiatric disorders precluding informed consent are excluded.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years; * Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors; * Use of spectral angio-CT image guidance as part of standard care; * Written confirmed consent. Exclusion Criteria: * Patients who are declared incapacitated; * Patients suffering from psychic disorders that make a comprehensive judgement impossible.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bone cancer metastatic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Assistance Publique Hopitaux de Paris - Hôpital Henri Mondor
NOT_YET_RECRUITINGCréteil, Île-de-France Region, 94000, France
-
Hospices Civils de Lyon - Hôpital Édouard Herriot
NOT_YET_RECRUITINGLyon, Auvergne-Rhône-Alpes, 69002, France
-
Leiden University Medical Center
RECRUITINGLeiden, South Holland, 2333 ZA, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI tailor recovery instructions after lung cancer surgery?
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
- Can a new radiation machine cut breath holds for cancer patients?
- Can two immunotherapy drugs make liver tumors more vulnerable to surgery?
- Can a new drug shield kidneys from chemotherapy damage?
- Radioactive tracer aims to spot kidney cancer with sharper eyes